Advancements in the Management of Gynecological Cancers: ESMO 2024 - Episode 11
Managing Recurrent Endometrial Cancer: Treatment Strategies and RUBY Trial Insights
Panelists review available treatment options for recurrent endometrial cancer, discussing their typical treatment approaches and the factors influencing treatment selection. Panelists also address insights from the RUBY trial, its updates, and the expanded FDA indication for dostarlimab, including the implications of these developments on treatment strategies and the potential benefits and challenges of broader use in patients.
Video Player is loading.
Video content above is prompted by the following:
- Briefly review the available treatment options for recurrent endometrial cancer.
- What is your typical treatment approach for patients with recurrent endometrial cancer, and what factors drive your treatment selection?
- In which patients do you opt for single-agent immunotherapy (IO) vs chemotherapy + IO, and what is your underlying rationale?
- Talking points: RUBY trial, part 2 of RUBY trial, GY018, DUO-E
- Dostarlimab, durvalumab + carboplatin + paclitaxel +/- olaparib, pembrolizumab
- Briefly comment on recent data updates presented for the RUBY trial and offer insights into the expanded FDA indication for dostarlimab in endometrial cancer.
- Briefly comment on key takeaways from extended efficacy and safety data leading to the expanded approval.
- How does the expanded indication approved for dostarlimab impact your treatment approach for advanced or recurrent endometrial cancer?
- What are the potential benefits and challenges of using dostarlimab in a broader patient population?
